CDMRP Neurofibromatosis Investigator-Initiated Research Program
ID: 355151Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355151
Timeline
    Description

    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is offering the Neurofibromatosis Investigator-Initiated Research Program grant to support innovative research projects aimed at advancing the understanding and treatment of neurofibromatosis (NF). This funding opportunity encourages high-impact research proposals that address clinical challenges associated with NF1, NF2, and schwannomatosis, with a total estimated program funding of approximately $5.36 million for FY24 and an expected six awards. Interested applicants, particularly those with a Principal Investigator at least at the Assistant Professor level, must submit pre-applications by September 12, 2024, and full applications by October 3, 2024, with peer reviews scheduled for December 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524NFRPIIRA_GG.pdf
    The DOD FY24 Neurofibromatosis Investigator-Initiated Research Award is a funding opportunity from the Department of Defense aimed at advancing research on neurofibromatosis (NF) to improve outcomes for affected individuals, including military personnel. The program seeks innovative and high-impact research proposals that address the clinical challenges of NF1, NF2, and schwannomatosis. The total funding for FY24 is approximately $25 million, with a maximum direct cost limit of $575,000 for Level 2 applications including a Qualified Collaborator or NF Open Science Initiative option. Pre-applications must be submitted by September 12, 2024, and full applications by October 3, 2024, with peer review occurring in December 2024. Applicants can be from diverse organizations, provided they meet eligibility criteria, particularly having a Principal Investigator at least at the Assistant Professor level. The review process consists of a peer evaluation focusing on the research strategy, impact, personnel qualifications, and budget, followed by a programmatic review to determine funding relevance. The initiative encourages collaboration, data sharing, and addressing critical needs within the NF community. The ultimate aim is to foster translational research that directly benefits Service Members, Veterans, and the general public by enhancing the understanding and treatment of neurofibromatosis.
    Similar Opportunities
    DoD Arthritis, Focused Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the DoD Arthritis Focused Research Award (Funding Opportunity Number: HT942524ATRPFRA) to support innovative research aimed at improving patient care for individuals affected by arthritis. This grant encourages applications that explore high-risk, high-reward research addressing various types of arthritis, including osteoarthritis and rheumatoid arthritis, with a particular focus on the implications for military personnel and their families. The total funding available for FY24 is approximately $2.5 million, with individual project budgets capped at $750,000 for Research Level 2 and $500,000 for Research Level 1. Interested applicants must submit a pre-application by October 16, 2024, and a full application by October 30, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DOD Glioblastoma, Resource Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Resource Development Award, aimed at enhancing research capabilities for glioblastoma, a malignant brain tumor. This grant supports the development of preclinical model systems that improve the understanding and treatment of glioblastoma, with a focus on innovative approaches such as animal models, organoids, and patient-derived xenografts. With a total funding pool of $4 million, the program anticipates awarding up to five grants, each capped at $500,000 over three years. Interested applicants must submit a pre-application by November 6, 2024, followed by a full application due by November 20, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DOD Glioblastoma, Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Hypothesis Development Award, aimed at funding innovative research to improve glioblastoma patient outcomes. This grant supports exploratory projects that address significant issues in glioblastoma research, particularly in areas such as drug delivery and biomarker identification, without requiring preliminary data. The total estimated funding for this program is approximately $4.64 million, with an expected 13 awards to be made, each with a funding limit of $200,000 for single principal investigators and $300,000 for partnering teams, over a performance period of up to two years. Interested applicants must submit a Letter of Intent by November 6, 2024, followed by a full application by November 20, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.
    DoD Reconstructive Transplant Research, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the FY24 Reconstructive Transplant Research Program (RTRP) Investigator-Initiated Research Award, aimed at advancing reconstructive transplant research and improving healthcare for military service members and veterans. This grant opportunity seeks proposals that focus on vascularized composite allotransplantation (VCA) and immunotherapy, emphasizing the optimization of immunosuppressive techniques, identification of noninvasive biomarkers for graft rejection monitoring, and development of tissue preservation strategies. With an estimated total program funding of $4 million, individual principal investigator applications can receive up to $1 million, while multiple principal investigator collaborations may secure up to $1.5 million, contingent upon successful peer review. The pre-application deadline is August 7, 2024, and the full application deadline is October 23, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Combat Readiness - Medical, Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Combat Readiness - Medical Translational Research Award (CRRP TRA) to support high-impact translational research aimed at enhancing medical readiness for military personnel. This funding opportunity seeks proposals that address critical areas such as battlefield diagnostics, treatments for life-threatening injuries, and operational health threats, with an emphasis on projects that leverage existing resources and demonstrate clear relevance to military health. The total estimated funding for this initiative is approximately $3.3 million, with the expectation of awarding around three grants, and key deadlines include pre-applications due by September 4, 2024, and full proposals by December 5, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Arthritis Research, Clinical Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Arthritis Research Clinical Research Award (ATRP CRA) to support clinical research aimed at improving the understanding and management of various forms of arthritis, particularly in military personnel and their families. This grant program encourages innovative research proposals that address disease-specific factors and interventions, with a focus on enhancing patient outcomes and informing clinical care or policy. With an estimated total funding of $6 million, the program anticipates awarding approximately three grants, including one for a clinical trial, with applications due by October 30, 2024, and a pre-application deadline of October 16, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Kidney Cancer, Academy of Kidney Cancer Investigators - Early-Career Scholar Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Academy of Kidney Cancer Investigators - Early-Career Scholar Award, aimed at fostering innovative kidney cancer research by supporting early-career scholars. This program encourages applicants to develop research projects that address critical areas in kidney cancer biology, novel therapies, and healthcare disparities, while providing intensive mentoring and networking opportunities within a collaborative Academy environment. With an estimated total program funding of $2.32 million, the initiative anticipates awarding approximately two grants, with applications due by October 15, 2024, following a pre-application letter of intent due by September 24, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Peer Reviewed Cancer, Advancing Cancer Care Through Clinical Trials Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a grant opportunity titled "DoD Peer Reviewed Cancer, Advancing Cancer Care Through Clinical Trials Award" for Fiscal Year 2024. This funding initiative aims to support the rapid implementation of clinical trials that have the potential to significantly impact cancer treatment and management, particularly for military personnel and their families, addressing specific topic areas related to military health. With an estimated total program funding of $24 million and the expectation of awarding up to five grants, eligible applicants can submit proposals that demonstrate the feasibility and relevance of their clinical trials, with a maximum award amount of $3 million. Interested parties must submit their applications by October 15, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Kidney Cancer, Idea Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Kidney Cancer Research Program's Idea Development Award, aimed at advancing innovative and high-impact kidney cancer research. This grant opportunity encourages projects that align with strategic goals such as enhancing understanding of kidney cancer biology, developing novel therapies, and addressing healthcare disparities, with a focus on benefiting active-duty military personnel, veterans, and the general public. The total estimated funding for this program is approximately $18.56 million, with around 13 awards anticipated, and key deadlines include a pre-application due by September 24, 2024, and a full application deadline of October 15, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Kidney Cancer, Translational Research Partnership Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Kidney Cancer Translational Research Partnership Award, a federal grant aimed at fostering collaborative research partnerships between clinicians and research scientists to advance kidney cancer treatment and care. This opportunity encourages the development of translational research projects that address significant problems in kidney cancer, requiring partnerships that include one clinician and one research scientist who contribute equally to the research design and execution. With an estimated total program funding of $7.68 million, the program anticipates awarding approximately six grants, each with a maximum budget of $800,000 over a three-year period. Interested applicants must submit a pre-application letter of intent by September 24, 2024, followed by a full application due by October 15, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.